PfSPZ (NF54) Challenge

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Plasmodium Falciparum Infection

Phase 1

PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States

CompletedNCT02773979

National Institute of Allergy and Infectious Diseases (NIAID)Plasmodium Falciparum Infection

Start: 2016-09-12End: 2018-01-22Updated: 2019-12-27

PfSPZ Challenge in Non-immune Adults in Baltimore, USA

CompletedNCT02780154

National Institute of Allergy and Infectious Diseases (NIAID)Plasmodium Falciparum Infection

Start: 2016-08-25End: 2016-12-15Updated: 2019-01-28

Safety and Efficacy of Sanaria's PfSPZ-CVac in Malian Adults

CompletedNCT02996695

National Institute of Allergy and Infectious Diseases (NIAID)Plasmodium Falciparum Infection

Start: 2017-04-06End: 2018-06-22Updated: 2019-12-02

Related Papers

PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial

EClinicalMedicine2022-07-3027 citations

PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection

PLoS Pathogens2021-05-2856 citations

Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): a study protocol to investigate <i>in vivo Plasmodium falciparum</i> malaria parasite growth in the context of pre-existing immunity.

2018-01-0134 citations